# Quadra Allure MP™ RF

# Merlin@home<sup>™</sup> Transmitter Compatible

# **Cardiac Resynchronisation Therapy Pacemaker**

# **Product Highlights**

- MultiPoint™ pacing delivers multiple LV pacing pulses per cardiac cycle and is designed to improve hemodynamic and clinical response
- The Quadra Allure MP™ RF CRT-P and Quartet™ quadripolar LV pacing lead feature four pacing electrodes and 14 pacing vectors to provide more options and greater control to address complications at and post implant to improve CRT response
- VectSelect Quartet™ multivector testing feature offers a streamlined workflow to identify, test and program the patient's pacing vector
- Angled header and physiologic tear drop shape provide better lead wrap
- CorVue™ Congestion Monitoring feature monitors the intrathoracic impedance and provides the option for both patient and physician alerts
- The DirectTrend™ Report provides a summary of three month daily, one year weekly or one year daily diagnostic trends
- Better patient unitilization from Day 1 when paired with the Merlin@home™ transmitter at point of care¹
- AT/AF Alerts can be programmed to notify patients and their clinics when a programmed AT/AF threshold or continuous episode duration has been exceeded, or when a high ventricular rate accompanies the AT/AF episode
- Exclusive AF Suppression™ algorithm is clinically proven to suppress episodes of paroxysmal and persistent AF
- AT/AF burden trend provides a graphical representation of the percentage of time in AT/AF and the number of AT/AF episodes in the previous 52 weeks
- Up to 14 minutes of stored electrograms help identify key intrinsic and pacemaker-related events and simplify the diagnosis of complex ECG rhythms associated with heart failure
- Longevity offers 8,2 years of service life supported by a 5 year warranty\*†

# Ordering Information

Contents: Cardiac pulse generator

Model Number	Dimensions (H x W x T, mm)	Weight (g)	Volume (cc)	Connector
PM3262	56 x 59 x 6	27	15	IS4-LLLL, IS-1

Indications: Implantation of a CRT-P is indicated in one or more of the following permanent conditions: syncope, presyncope, fatigue, disorientation due to arrhythmia/bradycardia, or any combinations of those symptoms. Implantation of a CRT-P is indicated for patients who would benefit from resynchronization of the right and left ventricles of have one or more conventional indications for the implantation of a pacemaker. \*\*Rate-Modulated Pacing\*\* is indicated for patients with chronotropic incompetence, and for those who would benefit from increased stimulation rates concurrent with physical activity. \*\*Dual-Chamber Pacing\*\* is indicated for those patients exhibiting: sick sinus syndrome, chronic, symptomatic second- and third-degree AV block, recurrent Adams-Stokes syndrome, symptomatic bilateral bundle branch block when tachyarrhythmia and other causes have been ruled out. \*\*Atrial Pacing\*\* is indicated for patients with sinus node dysfunction and normal AV and intraventricular conduction systems. \*\*Ventricular Pacing\*\* is indicated for patients with significant bradycardia and normal sinus rhythm with only rare episodes of A-V block or sinus arrest, chronic atrial fibrillation, severe physical disability. \*\*AF Suppression\*\* algorithm is indicated for suppression of paroxysmal or persistent atrial fibrillation episodes in patients with one or more of the above pacing indications.

Contraindications: Implanted Cardioverter-Defibrillator (ICD). Devices are contraindicated in patients with an implanted cardioverter-defibrillator. Rate-Adaptive Pacing may be inappropriate for patients who experience anging or other symptoms of myocardial dystunction at higher sensor-driven rates. An appropriate Maximum Sensor Rate should be selected based on assessment of the highest stimulation rate tolerated by the patient. AF Suppression stimulation is not recommended in patients who cannot tolerate high atrial-rate stimulation. Dual-Chamber Pacing, though not contraindicated for patients with chronic atrial flutter, chronic atrial fibrillation, or silent atria, may provide no benefit beyond that of single-chamber pacing in such patients. Single-Chamber Ventricular Demand Pacing is relatively contraindicated in patients who have

demonstrated pacemaker syndrome, have retrograde VA conduction, or suffer a drop in arterial blood pressure with the onset of ventricular pacing. Single-Chamber Atrial Pacing is relatively contraindicated in patients who have demonstrated compromise of AV conduction. Atrial Fibrillation. Allure<sup>™</sup> devices are contraindicated in patients having chronic atrial fibrillation or intermittent atrial fibrillation that does not terminate. For specific contraindications associated with individual modes, refer to the programmer's on-screen help.

Potential Adverse Events: The following are potential complications associated with the use of any pacing system: air embolism, body rejection phenomena, cardiac tamponade or perforation, hematoma, bleeding hematoma, seroma, formation of fibrotic tissue, local tissue reaction, inability to interrogate or program due to programmer or device malfunction, infection/erosion, interruption of desired pulse generator function due to electrical interference, either electromyogenic or electromagnetic, lead malfunction due to conductor fracture or insulation degradation, loss of capture or sensing due to lead dislotdgement or reaction at the electrode/ tissue interface, loss of desired pacing and/or sensing due to lead dislotdgement, body reaction at electrode interface, or lead malfunction (fracture or damage to insulation), loss of normal device function due to battery failure or component malfunction, pacemaker migration or pocket erosion, pectoral muscle or diaphragmatic stimulation, phrenic nerve stimulation, pneumothorax/hemothorax, endocarditis, excessive bleeding, induced atrial or ventricular arrhythmias, myocardial irritability, pericardial effusion, pericardial rub, pulmonary edema, rise in threshold and exit block, valve damage, cardiac/coronary sinus dissection, cardiac/coronary sinus perforation, coronary sinus or cardiac vein thrombosis.

Refer to the User's Manual for detailed indications, contraindications, warnings, precautions and potential



Ren X et al. Patient adherence in remote follow-up of cardiovascular implantable electronic devices. J Am Coll Cardiol. 2012;59:E645, doi: 10.1016/S0735-10097(12)60646-9.

<sup>\*</sup>Longevity calculated based on the following settings: 2,5V @ 0,4 ms (RA/RV/LV), 500 ohms, DDD, 60 BPM, 100% Bi-V Pacing, 100% Atrial Pacing and Stored EGMS on

 $<sup>^{\</sup>dagger}$ Battery impact of MultiPoint™ Pacing is dependent upon the output of the LV2 Pulse (for example LV2 = 2,5 V 0,4 ms results in an approximate 18% longevity impact.)

# Quadra Allure MP™ RF

## Cardiac Resynchronisation Therapy Pacemaker

# **Product Specifications**

PHYSICAL SPECIFICATIONS		
Model	PM3262	
Telemetry	RF	
Dimensions (mm)	56 x 59 x 6	
Weight (g)	27	
Volume (cc) <sup>1</sup>	15	
Connector	IS4-LLLL, IS-1	
PARAMETER	SETTINGS	

#### Resynchronisation Therapy

VectSelect Quartet™ LV Pulse Configuration Distal Tip 1-Mid 2; Distal Tip 1-Proximal 4; Distal Tip 1-RV Ring; Mid 2—Proximal 4; Mid 2—RV Ring; Mid 3—Mid 2; Mid 3—Proximal 4; Mid 3—RV Ring; Proximal 4—Mid 2; Proximal 4—RV Ring; Distal Tip 1—Can; Mid 2-Can; Mid 3-Can; Proximal 4-Can MultiPoint™ pacing Settings IV1-IV2

Delay 1: 5; 10; ...80ms Delay 2: 5; 10; ...50ms Delay MultiPoint pacing On: Off

V. Triggering options QuickOpt™ Timing Cycle Optimisation Intraventricular pace delay Sensed/Paced AV Delay; Interventricular Paced Delay 10–80 in steps of 5 0,05; 0,1–1,5 in steps of 0,1 RV and LV Pulse Width (ms) RV and LV Pulse Amplitude (V) RV Pulse Configuration

On; Off; Monitor

0,25 – 4,0 in steps of 0,25; 4,5 – 7,5 in steps of 0,5
Unipolar; Bipolar
BV Unipolar Tip; BV Bipolar; RV Unipolar Tip; RV Bipolar; Distal Tip 1–Mid 2; Ventricular Sense Configuration Distal Tip 1–Can; and Distal Tip 1–RV Tip Simultaneous; RV; LV

First Chamber Paced Negative AV Hysteresis Search (ms) Shortest AV/PV Delay (ms) Off; -10 to -120 in steps of 10  $25{-}50$  in steps of 5;  $60{-}120$  in steps of 10  $\,$ 

#### Output/Sensing Atrial ACap™ Confirm

Primary Pulse Confirmation Backup Pulse Confirmation Backup Pulse Amplitude (V) Binolar Bipolar 5,0 8; 24 Searchable Intervals (hrs) Atrial Pulse Configuration
Atrial Sense Configuration
Atrial Sensitivity<sup>3,4</sup> (Fixed) (mV) Unipolar (tip-case); Bipolar (tip-ring)
Unipolar (tip (tip-case); Bipolar (tip-ring); Unipolar Ring (ring-case)
0,1–0,5 in steps of 0,1; 0,75–2,0 in steps of 0,25; 2,5–5,0 in steps of 0,5 Atrial Pulse Amplitude (V) Atrial Pulse Width (ms) 0,1=0,0 in steps of 0,25; 4,5=7,5 in steps of 0,25; 0,05; 0,1=1,5 in steps of 0,1 On; Off; Monitor RVCap™ Confirm Searchable Interval (hrs) LVCap™ Confirm 8; 24 On; Off; Monitor Searchable Interval (hrs) 8; 24 Off; On (Automatic Sensitivity Control adjustment for atrial and ventricular events) 0,2–1,0 in steps of 0,1 Sense Ability™ Technology A Max Sensitivity (mV) 0,2—2,0 in steps of 0,1
0,2—2,0 in steps of 0,1
(Atrial and Ventricular Post-Sense) 50; 62,5; 75; 100%
(Atrial Post-Pace) 0,2—3,0 in steps of 0,1 mV
(Ventricular Post-Pace) Auto; 0,2—3,0 in steps of 0,1 mV
(Atrial and Ventricular Post-Sense) 0, 30; 60; 95; 125; 160; 190; 220
(Atrial Post-Pace) 0, 30; 60; 95; 125; 160; 190; 220 V Max Sensitivity (mV) Threshold Start Decay Delay (ms)

0,5-12,5 in steps of 0,5<sup>3,4</sup>

(Ventricular Post-Pace) Auto; 0; 30; 60; 95; 125; 160; 190; 220

Ventricular Sensitivity (fixed) (mV)

Rate/Timing A00(R); AAI(R); AAT(R); VOO(R); VVI(R); VVT(R); D00(R); DVI(R); DDI(R); DDD(R); VDD(R); Pacing Off DDT Trigger<sup>5</sup> DDT Timing<sup>5</sup> Base Rate (min<sup>-1</sup>) DDI 30–130 in steps of 5; 140–170 in steps of 10 Off; 30–150 in steps of 56 Off; 1; 5; 10; 15; 30 1–16 Hysteresis Rate (min-1) Search Interval (min) Cycle Count Off; Same Base Rate; 80-120 in steps of 10 (Intrinsic +0; Intrinsic +10; Intrinsic +20; Intrinsic +30) 1-10Intervention Rate (min-1) Intervention Duration (min-1) Fast: Medium: Slow: Very Slow Recovery Time Rest Rate (min<sup>-1</sup>) Maximum Tracking Rate (min<sup>-1</sup>) Off; 30–150 in steps of 5 90–130 in steps of 5; 140–180 in steps of 10 25; 30–200 in steps of 10; 225–325 in steps of 25 25; 30–200 in steps of 10; 225–300 in steps of 25; 350 Sensed AV Delay (ms) Paced AV Delay (ms) Ventricular Pace/Sense 125: 160-400 in steps of 30: 440: 470 Refractory7 (Fixed) (ms) Atrial Pace Refractory
Atrial Sense Refractory 190–400 in steps of 30; 440; 470<sup>8</sup> 93; 125; 157; 190–400 in steps of 30; 440; 470<sup>8</sup> PVARP (ms) 125-500 in steps of 25 Atrial Protection Interval (ms)5 Far-Field Protection Interval (ms)<sup>5</sup>

1 ± 0,5 cc.
2 If first with 10 ms interventricular delay,
3 Sensitivity is with respect to a 20 ms haversine test signal.
4 Sensitivity is with respect to a 20 ms haversine test signal.
4 Sensitivity is with respect to a 20 ms haversine test signal.
4 Sensitivity is with respect to a 20 ms haversine test signal.
4 Sensitivity is with respect to a 20 ms have signal.
5 Sensitivity is with respect to a 20 ms have signal.
5 Sensitivity is with respect to a 20 ms have signal.
6 Sensitivity is sensitivity in the sensitivity is sensitivity in the programmed base rate.
7 In dual-chamber modes, the maximum Vaniticular Refractory Period is 325 ms.
8 Programming options dependent on pacing mode.
9 During atrial MPS in dual-chamber modes, the shortest Coupling Interval will be limited by the programmed AW/PV Delay.
10 S1 Burst Cycle is applied at the preprigrammed S1 cycle length.

#### Customer Support: 46-8-474-4756

Brief Summary: Prior to using these devices, please review the Instructions for Use for a complete listing of indications, contraindications, warnings, precautions, potential adverse events and directions for use. D depicted may not be available in all countries. Check with your St. Jude Medical representative for product availability

Unless otherwise noted, ™ indicates that the name is a trademark of, or licensed to, St. Jude Medical or one of its subsidiaries. ST. JUDE MEDICAL and the nine-squares symbol are trademarks and service marks of St. Jude Medical, Inc and its related companies. © 2014 St. Jude Medical, Inc. All Rights Reserved. SJM-QD-1014-0002(1) | This document is for international use only.

#### Rate-Modulated

Rate Responsive AV/PV Delay Rate Responsive PVARP/VREF Shortest PVARP/VREF Off; Low; Medium; High Off; Low; Medium; High 125-475 in steps of 25 Sensor Max Sensor Rate (min<sup>-1</sup>) On; Off; Passive 80–150 in steps of 5; 160–180 in steps of 10

Auto (-0,5); Auto (+0,0); Auto (+1,5); Auto (+1,0); Auto (+1,5); Auto +(2,0); 1-7 in steps of 0,5 Auto (-1); Auto (+0); Auto (+1); Auto (+2); Auto (+3); 1-16 Threshold Slope Reaction Time

Very Fast; Fast; Medium; Slow Fast; Medium; Slow; Very Slow Recovery Time

#### **AF Management**

AF Suppression™ Algorithm Lower Rate Overdrive (min-1)5 Upper Rate Overdrive (min<sup>-1</sup>)<sup>5</sup> No. of Overdrive Pacing Cycles Rate Recovery (ms) Auto Mode Switch

15–40 in steps of 5 8:12 Off; DDD(R) to DDI(R); DDD(R) to DDT(R); DDD(R) to VVI(R); DDD(R) to VVT(R); VDD(R) to VVI(R); VDD(R) to VVT(R)

Off; On

AMS Base Rate (min-1) 40-170 in steps of 5

#### Stored Electrograms

Priority Options Off; Low; High 1; 2; 3 Channel Triggers Advanced Hysteresis Off; Low; High AMS Entry/AMS Exit/ AMS Entry and Exit AT/AF Detection Off; Low; High Off; Low; High Off; Low; High Off; Low; High 125–300 in steps of 25 Magnet Response High Atrial Rate Rate (min-1) No. of Consecutive Cycles High Ventricular Rate 2; 3; 4; 5; 10; 15; 20 Off; Low; High 125–300 in steps of 25 2; 3; 4; 5; 10; 15; 20 Off; Low; High Rate (min-1) No. of Consecutive Cycles PMT Termination Consecutive PVCs Off; Low; High No. of Consecutive PVCs Noise Reversion Off; Low; High

#### Other

Magnet Response Ventricular Intrinsic Preference, VIP™ (ms) VIP Search Interval VIP Search Cycles Atrial Tachycardia Detection Rate (min-1)

Post Vent. Atrial Blanking (PVAB) (ms) Ventricular Safety Standby **PVC** Response PMT Options PMT Detection Rate (min-1)

Stimulation Chamber Coupling Interval<sup>®</sup> (ms) S1 Count S110: S2; S3 and S4 Cycle (ms) Right Ventricular Support Rate (min-1)

Sinus Node Recovery Delay (s) Diagnostic Trends

CorVue™ Congestion Monitoring CorVue Congestion Trigger

Off; Battery Test

Off; 50-150 in steps of 25; 160-200 in steps of 1030 sec.; 1; 3; 5; 10; 30 min.

110-200 in steps of 10: 225-300 in steps of 25 60-200 in steps of 10; 225; 250

Off: On Off; Atrial Pace<sup>8</sup> Off; Passive; Atrial Pace<sup>8</sup> 90-180 in steps of 5 Uncoded; Unipolar; Bipolar

Atrial: Right Ventricular 200–800 in steps of 10 2–25 in steps of 1

Off; 100-800 in steps of 10 (Fixed or Adaptive)

Off: 30-95 in steps of 5

1–5 in steps of 1 AT/AF Activity; Exercise; Lead Impedance; P and R Wave; A and V threshold; CorVue™ Congestion Monitoring

Off- On

### **Patient Notifiers**

Programmable Notifiers (On; Off)

Device at ERI; Atrial Lead Impedance Out of Range; Ventricular Lead Impedance Out of Range; LV Lead Impedance Out of Range; AT/AF Burden; AT/AF Episode Duration; High V Rate During AT/AF, High V Rate, Percent BiV/RV Pacing Alert

Device Reset Entry into Backup VVI Mode

Audible Duration (sec) Number of Audible Alerts per Notification

Number of Notifications Time Between Notifications (hours) CorVue Congestion Monitoring Alert

2; 4; 6; 8; 10; 12; 14; 16

1\_16

